Related Experiment Videos
[Interleukin-2 immunotherapy and cutaneous manifestations]
B Larbre1, J F Nicolas, Y Sarret
1Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.
Annales De Dermatologie Et De Venereologie
|January 1, 1993
Abstract:
The cutaneous manifestations which follow the administration of recombinant interleukin-2 (rIL-2) are well known, but their nature and severity have not yet been fully studied. The authors report the dermatological changes observed in 12 patients treated with rIL-2 for renal cancer. The predominant lesion was generalized erythema followed by desquamation.